Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07125235 · ClinicalTrials.gov registry record · NA
Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical Trial
A NA study of Behavioral Intervention and ART Adherence, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- NA
- Development phase
- 270
- Enrollment target
- 1
- Study location
NCT07125235: Recruiting NA study of Behavioral Intervention and ART Adherence, sponsored by University of California, San Francisco.
NCT07125235 is a NA study of Behavioral Intervention and ART Adherence that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 270 participants, below the 5,417-participant average among 3 other Behavioral Intervention trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07125235, a NA study of Behavioral Intervention and ART Adherence, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- NA
- Development phase
- 270 participants
- Enrollment target
- 1
- Study location
Study Summary
Men who are living with HIV and use stimulants face many challenges and barriers that may interfere with remembering to take their HIV medication. Forgetting to take HIV medication puts men living with HIV at a greater risk of becoming virally unsuppressed. Researchers are doing this study to test if a remote intervention can help participants improve remembering to take their HIV medications and reduce the HIV viral load among men living with HIV who use stimulants.
Primary Outcome
The primary endpoint will be change in viral suppression comparing baseline to post-intervention viral load results measured by HIV-1 RNA, Quantitative, Real-Time PCR. Viral suppression is defined as viral load results that yield less than 50 copies/mL.
Conditions Studied
Interventions
- BEHAVIORAL reSTART Objective Adherence Self-Monitoring and Postive Affect mHealth Intervention
- DEVICE urine tenofovir point-of-care self-test
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2026-02-09 |
| Est. Completion | 2028-07-30 |
| Phase | NA |
What NCT07125235 shows while recruiting
NCT07125235 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 5,417-participant average among 3 other Behavioral Intervention trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Behavioral Intervention appearing as the primary indexed condition, and to 2 interventions - of which reSTART Objective Adherence Self-Monitoring and Postive Affect mHealth Intervention is the first listed.
NCT07125235 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07125235 about?
NCT07125235 is a clinical study titled "Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical Trial". Men who are living with HIV and use stimulants face many challenges and barriers that may interfere with remembering to take their HIV medication. Forgetting to take HIV medication puts men living with HIV at a greater risk of becoming virally unsuppressed. Researchers are doing this study to test i...
What is the current status of trial NCT07125235?
This trial is currently recruiting. It is a NA study. The enrollment target is 270 participants. The study started on 2026-02-09. Estimated completion is 2028-07-30.
What conditions does trial NCT07125235 study?
This clinical trial studies the following conditions: Behavioral Intervention, ART Adherence, Viral Suppression of HIV Infection.
What interventions are being tested in trial NCT07125235?
The interventions under investigation include: reSTART Objective Adherence Self-Monitoring and Postive Affect mHealth Intervention (BEHAVIORAL), urine tenofovir point-of-care self-test (DEVICE).
Who is sponsoring clinical trial NCT07125235?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07125235 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Behavioral Intervention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI